eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial

BACKGROUND: Bevacizumab plus chemotherapy is a widely used therapeutic option for first-line treatment of metastatic colorectal cancer (mCRC). However, molecular predictors of bevacizumab efficacy have not yet been identified. We analyzed vascular endothelial growth factor (VEGF) and endothelial nit...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Transl Med
Autores principales: Ulivi, Paola, Scarpi, Emanuela, Passardi, Alessandro, Marisi, Giorgia, Calistri, Daniele, Zoli, Wainer, Del Re, Marzia, Frassineti, Giovanni Luca, Tassinari, Davide, Tamberi, Stefano, Vertogen, Bernadette, Amadori, Dino
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4531503/
https://ncbi.nlm.nih.gov/pubmed/26259598
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-015-0619-5
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares